David Carbone, MD, PhD, director, James Thoracic Center, Ohio State University Comprehensive Cancer Center, discusses two abstracts on immunotherapy that were presented by colleagues at the 2019 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.

As a co-author on these abstracts, Carbone shared insight on the neoadjuvant study of atezolizumab (Tecentriq) before surgical resection in patients with lung cancer. The findings so far show correlation between immune biomarkers and progressive disease or patient response.

Another study presented at WCLC is a retrospective analysis of immunotherapy utilization in small cell lung cancer (SCLC). Carbone states that this study could also show an increase in the use of immunotherapy in SCLC.

Videos

David Carbone, MD, PhD, director, James Thoracic Center, Ohio State University Comprehensive Cancer Center, discusses two abstracts on immunotherapy that were presented by colleagues at the 2019 World Conference on Lung Cancer in Barcelona, Spain.

Dr. Carbone on Pivotal Immunotherapy Studies in Lung Cancer

David Carbone, MD, PhD, director of the James Thoracic Center, and professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses the effectiveness of different therapies to treat patients with lung cancer.

Many treatments in this space are based on a scientific knowledge of the cancers that allows oncologists to deliver highly effective therapies with lower toxicity than previously developed therapies, explains Carbone.

The challenge in the future of this treatment landscape, he says, will be converting this effectiveness into true cures, where a patient will never have to suffer and die from lung cancer. This may involve maintenance therapy, perhaps with sequential therapies, says Carbone. However, he says it is also important to note that this disease was once previously characterized as a painful, highly symptomatic cancer with a rapid progression to death. Now, with the development of so many novel treatments, significant progress is being achieved, and patients with lung cancer are seeing better and better outcomes.

David Carbone, MD, PhD, director of the James Thoracic Center, and professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses the effectiveness of different therapies to treat patients with lung cancer.


David Carbone, MD, PhD

Articles

Dr. Carbone on Pivotal Immunotherapy Studies in Lung Cancer

Dr. Carbone on Effectiveness of Different Lung Cancer Therapies